Tweet
Appears to be a cure for a few folks with rectal cancer.
https://www.npr.org/2022/06/07/11035...-immunotherapy
https://www.npr.org/2022/06/07/11035...-immunotherapy
-
YOB 1957
DX 12/18, GS 8, 4+4 6/12 cores, LL Apex 100%, LM Apex 60%, LL Mid 50%, LMM 40%, LL Base 5%, LM <5%, Right side negative.
3/6/19. Post surgery Pathology Report - Grade Group 4 Intraductal Carcinoma
T3aNO, <1 mm non focal EPE, GS8, 21 mm uni-focal tumor involved 10% of prostate.
7 Nodes, SV, SM, PNI, and BNI were negative.
LVI and Cribriform pattern present.
Decipher .86 High Risk.
Post Surgery PSA
3/25/19 .03. (25 days)
4/25/19 <.03. (2 months)
5/25/19 <.02 (3 months)
9/10/2019. <.02 (7 months)
11/27/2019. <.02. T < 3 (9 months)
5/19/2020. <.02 (15 months)
11/2/2020. <.02 (21 months)
5/11/2021. <.02 T <3 (27 months)
8/25/2021. <.02 T <3 (30 months)
12/6/2021. <.02 T <3 (33 months)
6/14/2022. <.02 T <3 (39 months) T=37
3 Part Modality Treatment Completed
2/25/19 Robotic Laparoendoscopic Single Site Surgery outpatient Cleveland Clinic, Dr. Kaouk, surgery #41 in US.
ART - 7/25/-9/25 2019 (78 Gy, yes, I glow in the dark).
ADT - 5/19- 5/21 Eligard and Casodex.
3 Part Modality Treatment Completed
2/25/19 Robotic Laparoendoscopic Single Site Surgery outpatient Cleveland Clinic, Dr. Kaouk, surgery #41 in US.
ART - 7/25/-9/25 2019 (78 Gy, yes, I glow in the dark).
ADT - 5/19- 5/21 Eligard and Casodex.
-
That's amazing.. I pray science continues to evolve and we get more cures.Wife posting - DOB 5/76- Black Male
PSA Hist:
1/2018 2.66
1/2019 3.39
Retest 2/019 3.04
MRI 3/2019: 3 Lesions identified (1) Pirads 4 & (2)Pirads3
MRI Guided Biopsy 4/11/2019: G6(3+3)
RMB: 10% of 1 core
RMM: 10% of the tissue (fragmented specimen).
RMA: High-grade prostatic intraepithelial neoplasia.
RLB: 25% of 1 core.
RLM: 70% of tissue
RLA: 50% of 1 core.
LMB: 80% of 1 core.
Lesion #2, in 3 of 3 cores, 80% of total tissue
RALP 6/5/19 USMD Arlington Dr. R. Parham
Cath 6 days, bladder spasms, cath back in for 5 days
No incontinence/Minimum ED (using Sildenafil as needed)
Final Path 6/11/19: G6(3+3)
SV, BNI, Adipose Tissue, ECE, Margins, PNI, LVI, LNI(0of8) All Negative
PT2N0 ~10% involved by tumor
Quest Diagnostics uPSA:
9/7/19 (3mths) <0.02
1/4/20 (7mths) <0.1 & <0.02
1/20/20 Annual physical <0.02
6/6/20 (1yr) <0.02
12/5/20(18mths) <0.02
6/5/21(2Yr) <0.1
1/17/22(31mths) 0.009-Clinical Path Lab ultrasensitive
6/9/22(3 years)<0.04
-
I've read about this recently in several other forums. It appears to be effective only in specific cases of a DNA repair mismatch gene.Originally posted by Duck2 View Post
Casualty of 2012 USPSTF recommendationsComment
Comment